RecruitingPhase 4NCT05644717

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Getz Pharma
Principal Investigator
Umar Raja, MBBS
Shifa International Hospital
Intervention
Ertugliflozin 5 mg, 15mg(drug)
Enrollment
164 target
Eligibility
18-65 years · All sexes
Timeline
20232025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05644717 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

← Back to all trials